Opportunities for Guiding Neoadjuvant Treatment Decisions with ctDNA in MIBC
The panelists propose a nuanced view of molecular testing, suggesting ctDNA's value lies in its positive predictive capacity for identifying advanced disease, while utDNA may offer stronger negative predictive insights.
The panelists propose a nuanced view of molecular testing, suggesting ctDNA's value lies in its positive predictive capacity for identifying advanced disease, while utDNA may offer stronger negative predictive insights. They explore the challenges of field cancerization in bladder cancer, discussing how different molecular testing platforms might provide complementary information. The experts emphasize the complexity of interpreting molecular markers, highlighting the need for sophisticated, integrated approaches. Their dialogue reveals the evolving landscape of precision medicine, showcasing how multiple testing strategies can offer more comprehensive disease understanding. They critically examine the limitations of current diagnostic methods, discussing how advanced molecular profiling could potentially overcome existing challenges. The discussion emphasizes the importance of developing more refined, patient-specific molecular testing strategies.
